Sacituzumab Govitecan Plus Enfortumab Vedotin for Metastatic Urothelial Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma
Ann. Oncol 2024 Jan 01;35(1)91-97, BA McGregor, GP Sonpavde, L Kwak, MM Regan, X Gao, H Hvidsten, CM Mantia, XX Wei, JE Berchuck, SA Berg, PK Ravi, MD Michaelson, TK Choueiri, J BellmuntFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.